Trials / Completed
CompletedNCT01110629
Study in Chronic Kidney Disease (CKD) Not on Dialysis
Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lanthanum Carbonate 750 to 2250 mg in Patients With Chronic Kidney Disease Not on Dialysis Who Develop Hyperphosphatemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 143 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to investigate the efficacy and safety of lanthanum carbonate 750 to 2,250 mg in Japanese Chronic Kidney Disease Stage 3, 4 and 5 subjects not on dialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fosrenol (Lanthanum Carbonate, BAY77-1931) | Daily dose: 750-2250mg 3 times a dayfor 8 weeks. |
| DRUG | Placebo | daily dose: 3 tablets TID for 8 weeks. |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2010-04-26
- Last updated
- 2014-10-15
Locations
40 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01110629. Inclusion in this directory is not an endorsement.